Overall survival data from PACIFIC trial of Imfinzi for NSCLC is published in NEJM. AstraZeneca

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi (durvalumab) during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Toronto, Canada.

Results from the Phase III PACIFIC trial were published simultaneously in the New England Journal of Medicine, showing Imfinzi (durvalumab) significantly improved OS, the second primary endpoint of the trial, compared to standard of care regardless of PD-L1 expression, reducing the risk of death by 32% (HR 0.68, 99.73% CI 0.47-0.997; p=0.0025). Detailed results are published online in the New England Journal of Medicine.

Scott J. Antonia, MD, Ph.D., chair of the Thoracic Oncology Department at Moffitt Cancer Center in Tampa, Florida, USA and principal investigator in the PACIFIC trial said: �The five-year survival rate in this setting has historically been around 15% after concurrent chemoradiation therapy. The significant survival benefit observed using the PACIFIC regimen provides confidence and clear rationale for a new standard of care.�

See- "Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC"- Scott J. Antonia, M.D., Ph.D., Augusto Villegas, M.D., , et al., for the PACIFIC Investigators.-September 25, 2018 DOI: 10.1056/NEJMoa1809697.